Recent developments in immunotherapy of cancers caused by human papillomaviruses

Elham Fakhr,1,2 Ziva Modic1 and Angel Cid-Arregui1
1Targeted Tumor Vaccines, German Cancer Research Center (DKFZ), Heidelberg, Germany, 2Registered at Faculty of Biosciences, Heidelberg University, Heidelberg, Germany

doi:10.1111/imm.13285
Received 10 July 2020; revised 22 October 2020; accepted 25 October 2020.
Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
Correspondence
Angel Cid-Arregui, Targeted Tumor Vaccines, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Email: a.cid@dkfz-heidelberg.de

Abstract
A subset of oncogenic human papillomaviruses (HPVs) is the main cause of genital cancers, most importantly cervical cancer and an increasing number of head and neck cancers. Despite the availability of prophylactic vaccines against the most prevalent oncogenic HPV types, HPV-induced malignancies are still a major health and economic burden. Besides conventional treatment with surgery, chemotherapy and radiation, immunotherapy is emerging as an efficient adjuvant option. Here, we review relevant studies and ongoing clinical trials using immune checkpoint inhibitors, therapeutic vaccines, gene editing approaches and adoptive T cell therapies, with special focus on engineered TCR T cells, which are showing encouraging results and could lead to significant improvement in the treatment of HPV+–infected cancer patients.

Keywords: cervical cancer; Engineered TCR T cells; human papillomavirus; immunotherapy.

INTRODUCTION

Human papillomaviruses (HPV) are small, non-enveloped DNA viruses that belong to the family of Papillomaviridae, which consists of 52 genera and nearly 200 virus types. The most extensively studied are those of the genus Alphapapillomavirus, which is divided into high-risk types (HR-HPVs), most importantly HPV16 and HPV18, classified as carcinogenic (IARC Group 1), and low-risk HPV types that cause mild dysplasia and benign tumours.1,2 The genome of the HPVs is circular, double-stranded molecule of approximately 8 kb, divided into three regions: long control region (LCR) involved in the regulation of viral gene expression; early (E) region encoding non-structural proteins needed for viral replication and survival; and finally, late (L) region encoding two structural capsid proteins. Most HR-HPV infections regress spontaneously; however, in about 10% of cases the immune system fails to clear the infection, which persists and may cause malignant transformation. In such cases, the viral DNA can get randomly integrated into the host genome,3,4 usually causing disruption of the E2 gene, which otherwise encodes as a transcriptional repressor of the early gene promoter in the LCR, leading to deregulated expression of the main HR-HPV oncogenes – E6 and E7.5–7 These two proteins target several intracellular...
signalling pathways involved in cell cycle regulation, apoptosis, maintenance of genomic integrity and DNA repair.8–12

According to data from GLOBOCAN 2018,13 persistent infection with HR-HPV types is linked to approximately 4.5% of all cancer cases globally. HR-HPVs are recognized as the main causative agent of cervical, anal, vulvar, vaginal and penile cancers. Moreover, they are linked to an increasing number of head and neck cancers as well.14 Three prophylactic vaccines have been approved to date (quadrivalent Gardasil®, nonavalent Gardasil-9® and bivalent Cervarix®) made of virus-like particles of the most frequent HR-HPV types, the latter also including two LR-HPV types that cause genital warts. It has been estimated that the non-valent vaccine could potentially prevent up to 90% of HPV-related cancers.15 However, there is still a need for effective therapies to treat advanced cases. Cervical cancer is the fourth most common type of cancer and the fourth leading cause of cancer mortality among women worldwide.13 Recently, immune-directed therapies applied to advanced HPV-positive cancers have shown significant success. Here, we review various immunotherapeutic approaches applied to HPV-associated cancer patients in clinical trials, with special focus on engineered TCR T cells. Our review follows the flow chart shown in Figure 1.

**IMMUNE CHECKPOINT INHIBITORS**

Inhibitors targeting two negative immune regulatory pathways of T cells, the programmed death receptor 1 (PD-1) and its ligand (PD-L1) and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have been assessed in clinical trials as having high therapeutic potential.16 There are several ongoing clinical trials with anti-PD-1/ PD-L1 and anti-CTLA-4. Immune checkpoint inhibitors can be used solely or in combination with chemotherapy, chemoradiation and antiangiogenic agents. Ongoing clinical trials related to anti-PD-1/ PD-L1 and anti-CTLA-4 for HPV (+) cancers are summarized in Tables 1 and 2, respectively.

**Anti-PD-1/PD-L1 monoclonal antibodies**

Nivolumab, a fully human antibody against PD-1, has been tested as a monotherapy in patients suffering from recurrent or metastatic cervical cancer (NCT02257528). The results of this study showed that solely administration of nivolumab was safe but had low antitumour effect.17 However, the initial results of another phase I/II clinical study (NCT02488759) have shown that the efficacy of nivolumab monotherapy is promising in metastatic vaginal, vulvar and cervical cancers.18 The efficiency and safety of nivolumab plus chemoradiation...
(NCT03298893) and in combination with paclitaxel (NCT04282109) are being studied in patients suffering from locally advanced cervical cancer or recurrent head and neck squamous cell carcinoma (HNSCC), respectively. The results of these studies have not been reported yet, but the combo therapies are expected to be more effective than nivolumab alone.

Pembrolizumab is a humanized antibody targeting PD-1 that has shown promising outcomes in a clinical phase II study as monotherapy of metastatic solid tumours including cervical and vulvar cancers. The antitumour activity of pembrolizumab in patients with PD-L1-positive advanced cervical cancer was stable, and the toxicity was manageable (NCT02628067). Based on these findings, the US Food and Drug Administration has accelerated the approval of pembrolizumab for PD-L1-positive advanced cervical cancer suffering from progression in the course of chemotherapy or afterwards. Furthermore, in a phase III clinical trial, pembrolizumab monotherapy also showed encouraging results in PD-L1-positive recurrent or metastatic HNSCC. The published results also support that pembrolizumab in combination with 5-fluorouracil and platinum chemotherapy can be considered as a first-line treatment for HNSCC.

In yet another phase III clinical trial, the safety and antitumour activity of pembrolizumab is being studied in combination with platinum-based chemotherapy in patients with recurrent, persistent or metastatic cervical cancer (NCT03635567). The study is planned to be completed on November 2022, and it is expected to provide valuable information on the suitability of this therapeutic regime as the first-line treatment for recurrent or metastatic cervical cancer. In a phase II study, durvalumab, anti-PD-L1, is being combined with a personalized

| Table 1. Ongoing clinical trials of anti-PD-1/PD-L1 for the treatment of HPV-associated cancers |
|---------------------------------------------------------------|
| **Agent(s)** |
| **Type** |
| **Clinical phase** | **Start date** | **Completion date** | **Clinical trial reference** |
| Nivolumab | Anti-PD-1 | II | May 2015 | Mar. 2019<sup>a</sup> | NCT02257528 |
| Nivolumab /ipilimumab /daratumumab /relatlimab | Anti-PD-1 /Anti-CTLA-4 /Anti-CD 38 /Anti-LAG-3 | I/II | Oct. 2015 | May 2022 | NCT02488759 |
| Nivolumab /cisplatin /radiotherapy | Anti-PD-1 /chemotherapy | I/II | Nov. 2017 | April 2020 | NCT03298893 |
| Nivolumab /cisplatin /radiotherapy | Anti-PD-1 /chemotherapy | II | June 2020 | Aug. 2023 | NCT04282109 |
| Pembrolizumab | Anti-PD-1 | II | Dec. 2015 | Aug. 2023 | NCT02628067 |
| Pembrolizumab /paclitaxel/cisplatin/carboplatin/bevacizumab/Placebo | Anti-PD-1 /platinum-based chemotherapy /antiangiogenic agents | III | Oct. 2018 | Nov. 2022 | NCT03635567 |
| Pembrolizumab /platinum /brachytherapy | Anti-PD-1 /chemotherapy /radiotherapy | I | Dec. 2017 | Jan. 2019 | NCT03144466 |
| Pembrolizumab /cisplatin /brachytherapy | Anti-PD-1 /chemotherapy /chemoradiation | II | Jan. 2016 | May 2021 | NCT02635360 |
| Pembrolizumab /paclitaxel/cisplatin/carboplatin/bevacizumab | Anti-PD-1 /platinum-based chemotherapy /antiangiogenic agents | II | Sept. 2018 | Oct. 2025 | NCT03367871 |
| Pembrolizumab /immunomodulatory /cocktail /radiotherapy | Anti-PD-1 /vitamin D, aspirin, cyclophosphamide and lansoprazole | II | July 2017 | June 2022 | NCT03192059 |
| AGEN2034 (RebmAb-700) | Anti-PD-1 | I/II | April 2017 | Sept. 2019 | NCT03104699 |
| REGN2810 (cemiplimab) | Anti-PD-1 | I/II | April 2017 | Sept. 2019 | NCT03257267 |
| Durvalumab /vigil | Anti-PD-L1 /cellular immunotherapy | II | June 2016 | Jan. 2021<sup>a</sup> | NCT02725489 |
| M7824 | Bifunctional antibody targeting TGF-β and PD-L1 | II | Feb. 2018 | Dec. 2023 | NCT03427411 |
| Atezolizumab /carboplatin /cyclophosphamide | Anti-PD-L1 /chemotherapy | I | Jan. 2017 | June 2019<sup>a</sup> | NCT02914470 |
| Atezolizumab /cisplatin/paclitaxel /bevacizumab | Anti-PD-L1 /chemotherapy /antiangiogenic agents | III | Sept. 2018 | Dec. 2023 | NCT03556839 |
| Atezolizumab /bevacizumab | Anti-PD-L1 /antiangiogenic agents | II | Mar. 2017 | Aug. 2020<sup>a</sup> | NCT02921269 |

<sup>a</sup>Active, not recruiting.
cellular immunotherapy called vigil in advanced cancers including cervical carcinomas (NCT02725489). Vigil consists of irradiated autologous tumour cells genetically engineered to suppress transforming growth factor-β1 and transforming growth factor-β2 (TGF-β1 and TGF-β2) and express recombinant human granulocyte–macrophage colony-stimulating factor (rhGM-CSF). Moreover, in another phase II study, M7824, a bifunctional antibody targeting TGF-β and PD-L1, is being studied in HPV-associated cancers (NCT03427411). A combinational therapy of chemotherapeutic drugs, carboplatin–cyclophosphamide and atezolizumab (anti-PD-L1), is under study in a phase I study (NCT02914470). Further, in an active, recruiting phase III clinical trial, atezolizumab is combined with cisplatin/paclitaxel/bevacizumab, a standard treatment of stage IVB cervical carcinoma (NCT03556839).21 In addition, in a running phase II clinical study, bevacizumab is combined with atezolizumab in advanced cervical cancers. Interestingly, this study includes intratumoral and peripheral T cell receptor (TCR) clonality assessment by TCR sequencing (NCT02921269).

**Anti-CTLA-4 monoclonal antibodies**

Upon ligand binding on activated T cells, CTLA-4 down-modulates their cytotoxic responses. It has been shown recently that single nucleotide polymorphisms in the promoter region of the CTLA-4 gene correlate with higher susceptibility to various types of malignancies including cervical cancer.22 Ipilimumab, a fully human anti-CTLA-4 monoclonal antibody, is being tested in a phase II study to assess its efficacy in patients with recurrent or metastatic cervical cancer (NCT01693783). Initial results on 34 evaluated patients showed three partial responses and eight cases with stable disease, while 23 patients had progression of disease. Moreover, ipilimumab was well tolerated in cervical cancer patients and promoted immune activation.23 Another phase I study recruits patients with locally advanced cervical cancer to receive chemotherapy with cisplatin and chemoradiation followed by administration of ipilimumab. This study will measure HPV-specific T cells and differential activated T cell responses based on the HLA-subtype A*0201 (NCT01711515). According to an initial report on 2017, ipilimumab was efficient and well tolerated.24 Safety and dosage of ipilimumab in combination with cetuximab is also being studied in patients with stage III/IVB head and neck cancer (NCT01935921).

In yet another approach, anti-PD-1/PD-L1 and anti-CTLA-4 antibodies are used simultaneously. An active phase I study was designed to evaluate the safety and tolerance of tremelimumab, anti-CTLA-4 antibody and durvalumab in various advanced solid tumours including cervical cancer (NCT01975831). Preliminary results showed that this combination is safe and has clinical activity.25 Combination of nivolumab, ipilimumab and radiotherapy is also being evaluated in HPV-positive head and neck cancer (NCT01935921).

In yet another approach, anti-PD-1/PD-L1 and anti-CTLA-4 antibodies are used simultaneously. An active phase I study was designed to evaluate the safety and tolerance of tremelimumab, anti-CTLA-4 antibody and durvalumab in various advanced solid tumours including cervical cancer (NCT01975831). Preliminary results showed that this combination is safe and has clinical activity.25 Combination of nivolumab, ipilimumab and radiotherapy is also being evaluated in HPV-positive head and neck cancer (NCT01935921).

Table 2. Ongoing clinical trials of CTLA-4 inhibitors for the treatment of HPV-associated cancers

| Agent(s) | Type | Clinical phase | Start Date | Completion Date | Clinical trial reference |
|----------|------|----------------|------------|-----------------|-------------------------|
| Ipilimumab | Anti-CTLA-4 | II | Dec. 2012 | Dec. 2020* | NCT01693783 |
| Ipilimumab /cisplatin /radiation | Anti-CTLA-4/chemotherapy | I | Oct. 2012 | Mar. 2017* | NCT01711515 |
| Ipilimumab /cetuximab /radiotherapy | Anti-CTLA-4 /antiangiogenic /radiotherapy | I | Apr. 2013 | Oct. 2016* | NCT01935921 |
| Tremelimumab /durvalumab | Anti-CTLA-4 /anti-PD-L1 | I | Dec. 2013 | Dec. 2020* | NCT01975831 |
| Nivolumab /ipilimumab /radiotherapy | Anti-PD-1 /Anti-CTLA-4 /radiotherapy | II | July 2013 | Aug. 2022 | NCT03799445 |
| Tremelimumab /durvalumab /vinorelbine | Anti-CTLA-4 /anti-PD-L1 /chemotherapy | I/II | Jun 2018 | Aug. 2023 | NCT03518606 |
| Tremelimumab /durvalumab /radiotherapy | Anti-CTLA-4/anti-PD-L1 /radiotherapy | I | July 2013 | Oct. 2020 | NCT03452332 |

*NCT0195921: Active, not recruiting.*

© 2020 The Authors. Immunology published by John Wiley & Sons Ltd, Immunology, 163, 33–45
THERAPEUTIC VACCINES

Most therapeutic HPV vaccines target the two major oncoproteins of HPV16 and HPV18, E6 and E7, which are constitutively expressed by tumour cells. A number of strategies have been applied to develop therapeutic vaccines using vectors, peptides/proteins, DNA and genome editing tools. Vector, peptide and protein vaccines are mainly HPV16-specific, while DNA vaccines and genome editing tools are mostly polyclonal vaccines targeting E6 and E7 genes of both HPV16 and HPV18. Table 3 summarizes recent clinical studies using vaccines.

Vector vaccines

Certain recombinant bacterial and viral vectors can replicate inside the cells and promote antigen presentation. ADXS11-001 is an attenuated live Listeria monocytogenes (LM) encoding a HPV16 E7 oncoprotein linked to LM listeriolysin O, which has been evaluated in several clinical trials for the treatment of HPV16(+) cancers including cervical cancer. ADXS11-001 monotherapy has shown promising outcomes in terms of safety and efficacy in recurrent cervical cancer patients (NCT01266460). The first stage of these two-stage phase II clinical study showed 12-month overall survival for 38.5% of the patients. In the second stage, 12-month overall survival rate and these outcomes encourage further clinical studies of ADXS11-001. In a phase III clinical trial, this vaccine was also compared with placebo in disease-free interval of patients with high-risk locally advanced cervical cancer (NCT02853604). ADXS11-001 is also being studied in HPV-positive head and neck cancers to evaluate whether it can simulate the immune system prior to surgery (NCT02002182). A recent completed phase I/II trial with ADXS11-001 showed that 1 × 10^9 colony-forming units (CFU) could be safely administered to patients with advanced anal cancer and that the vaccine, solely or in combination with cisplatin, had antitumour activity (NCT01671488). Another phase I/II study showed the safety of a higher dose of ADXS11-001 (1 × 10^10 CFU) in cervical cancer patients at different stages (NCT02164461). In a phase I/II clinical trial, the same vaccine was administered alone or in combination with durvalumab in previously treated locally advanced or metastatic cervical or head and neck cancer patients (NCT02291055). ADXS11-001, as monotherapy or in combination, has shown encouraging outcomes, and the results of more clinical studies can pave its path to be approved as an alternative therapy for HPV-positive cancer patients.

Modified vaccinia virus Ankara (MVA) vectors encoding E6 or E7 oncoprotein of HPV16 or HPV18 have been shown to drive HPV-specific cytotoxic T-lymphocyte (CTL) responses. TG4001 is a MVA vector expressing HPV16 E6/E7 and IL-2, which is currently being evaluated in a phase I/II trial (NCT03260023) in HPV16(+) recurrent or metastatic cancers in combination with avelumab, a humanized IgG1 monoclonal antibody targeting human PD-L1. Interim results suggest that administration of TG4001 plus avelumab in HPV16+ cancer patients is safe and induces antitumour activity.

Vvax001 is an RNA replicon derived from Semiliki Forest virus encoding a fusion of the HPV16 E6 and E7 proteins that is being tested for the first time in humans to evaluate its efficacy and safety in advanced cervical cancer in a running clinical study (NCT03141463). TA-HPV is a live recombinant vaccinia virus expressing modified E6/E7 genes of HPV16/18. Based on the result of a phase I clinical study, TA-HPV in combination with pNGVL4a-Sig/E7 (detox)/HSP70 DNA vaccine and imiquimod is well tolerated, and can induce effector immune response in HPV16+ CIN III patients (NCT00788164).

PRGN-2009 is a novel gorilla adenovirus including multiple E6/E7 epitopes of HPV16 and HPV18. Due to its promising preclinical results, it is being evaluated in HPV (+) cancer patients (NCT04432597).

Peptide and protein vaccines

Peptide vaccines use identified MHC class I-restricted immunogenic epitopes from HPV antigens. DPX-E7 is a 9-amino-acid-long synthetic peptide, HPV16 E7_{11-19}, packaged into liposomes, freeze-dried and resuspended in oil. DPX-E7 efficacy is being tested in an open-label phase Ib/II trial in HLA-A*02-01 patients with HPV16-associated head and neck, anal and cervical cancers (NCT02865135).

ISA101 (ISA Pharmaceuticals) is a synthetic long peptide (SLP) vaccine consisting of 12 SLPs (25–35 residues each) from the E6 and E7 oncoproteins of HPV16. ISA101 is being studied combined with nivolumab in patients with HPV16-positive solid tumours in a phase II trial (NCT02426892). Based on the overall response rate and median overall survival, the results showed promising outcomes compared with solo administration of anti-PD-1. In another phase I/II clinical study, ISA 101 is used in combination with pegylated interferon (IFN-α, 1lb). Their results showed that there is a significant correlation between overall survival and T cell responses induced by the vaccine. Hespera is another vaccine of the same company consisting of two HPV16 E6-derived SLPs conjugated to a synthetic Toll-like receptor 2 (TLR2) ligand (Amplivant). Dose-escalation, toxicity and ability to induce HPV16 E6-specific T cell responses of Hespera are being tested in a phase I study (NCT02821494).

PepCan is a vaccine consisting of four HPV16 E6 peptides, which was designed as therapy for high-grade squamous intraepithelial neoplasia (HSIL). It was safe in a phase I study combined with a Candida skin test reagent
| Agent | Type | Agent Type | Start Date | Completion Date |
|-------|------|------------|------------|----------------|
| ADXS11-001 | Bacterial vector | HPV16 E7 | May 2013 | Oct 2018 |
| ADXS11-001 /placebo | Bacterial vector | HPV16 E7 | Sept. 2016 | Oct. 2024 |
| ADXS 11-001 | Bacterial vector | HPV16 E7 | Dec. 2013 | Aug. 2023 |
| ADXS11-001 /5-fluorouracil/mitomycin | Bacterial vector / chemotherapy | HPV16 E7 | Feb. 2013 | Feb. 2018 |
| ADXS11-001 | Bacterial vector | HPV16 E7 | Jan. 2015 | July 2018 |
| ADXS11-001 /durvalumab | Bacterial vector /anti-PD-L1 | HPV16 E7 | Apr. 2015 | Dec. 2019 |
| TG4001/avelumab | Viral vector/anti-PD-L1 | HPV-16 E6/E7 | Feb. 2013 | Feb. 2018 |
| Vvax 001 | RNA replicon vaccine | HPV-16 E6/E7 | Jan. 2017 | Nov. 2017 |
| TA-HPV/pNGVL4a-Sig/E7 (detox)/HSP70/iminiquimod PRGN-2009/M7824 | Viral vector /DNA vaccine /immune response modifier | HPV-16/18 E6/E7 | Nov. 2008 | Dec. 2021 |
| DPX-E7 | Peptide vaccine | HPV-16 E6/E7 | Aug. 2020 | Oct. 2023 |
| ISA 101 /Nivolumab | Peptide vaccine/anti-PD-1 | HPV-16 E6/E7 | Sep. 2013 | Aug. 2018 |
| ISA 101 /carboplatin/paclitaxel /bevacizumab PepCan | Peptide vaccine /chemotherapy /antiangiogenic | HPV-16 E6/E7 | Oct. 2015 | Oct. 2020 |
| Hespecta | Peptide vaccine | HPV16 E6 | Mar. 2015 | Dec. 2017 |
| HPV16 E7 peptide, synthetic HPV16 E6 peptide | Peptide vaccine | HPV16 E6/E7 | Jan. 2003 | Apr. 2015 |
| TA-CIN | Protein vaccine | HPV16 E6/E7 | Apr. 2019 | Nov. 2022 |
| TVGV-1 | Protein vaccine | HPV16 E6 | Nov. 2015 | Sept. 2018 |
| GX-118E | DNA vaccine | HPV16/18 E6/E7 | July 2014 | Mar. 2016 |
| GX-118E/placebo | DNA vaccine | HPV16/18 E6/E7 | Aug. 2015 | Aug. 2018 |
| GX-118E/GX-I7/imiquimod | DNA vaccine /IL-7 /antigenal warts | HPV16/18 E6/E7 | May 2017 | Oct. 2018 |
| VGX-3100 /INO-9012 | DNA vaccine /DNA vaccine encoding IL-12 | HPV16/18 E6/E7 | May 2014 | Sept. 2017 |
| VGX-3100 /placebo | DNA vaccine | HPV16/18 E6/E7 | June 2017 | Apr. 2021 |
| VB10.16 | DNA vaccine | HPV16 E6 | Aug. 2015 | Jan. 2019 |
| pnGVL4a-CRT/E7 (Detox) | DNA vaccine | HPV16 E7 | Oct. 2009 | July 2018 |
| pnGVL4a-CRT/E7 (Detox)/cyclophosphamide | DNA vaccine /chemotherapy | HPV16 E7 | Dec. 2011 | Nov. 2018 |
as adjuvant.\(^3\) The efficacy and safety of PepCan is currently being evaluated in a phase II study in patients with HSIL (NCT02481414).

In contrast to peptide vaccines, protein vaccines include all antigenic epitopes of E6/E7. Yet, they are less immunogenic and induce mainly MHC class II presentation.\(^4\) However, vaccines using fusion proteins are more immunogenic and promote presentation through MHC I pathway and subsequent activation of CTLs.\(^4\) TA-CIN is a vaccine consisting of an HPV16 L2/E6/E7 fusion protein, which is currently being evaluated in a phase I study in patients with HPV16 (+) cervical cancer (NCT02405221). TVGV-1 is another fusion protein vaccine consisting of peptide sequence of human HPV16 E7 fused to the \textit{Pseudomonas aeruginosa} exotoxin A and an endoplasmic reticulum retention signal (KDEL), combined with GPI-0100 as adjuvant. Its efficiency and safety are being studied in a phase II trial enrolling HPV16/18 (+) HSIL patients (NCT02576561).

DNA vaccines

DNA vaccines have been tested in different clinical studies and demonstrated to be safe, but they generally act as poor immunogens.\(^4\) Therefore, strategies to improve their processing and presentation of antigens encoded by DNA vaccines have been developed to improve their immunogenicity. GX-188E (Genexine, Inc.) is one such vaccine consisting of a tissue plasminogen activator signal sequence, an FMS-like tyrosine kinase 3 ligand, and shuffled E6 and E7 genes of HPV16 and HPV18. Safety and efficiency of GX-118E, applied intramuscularly by electroporation, has been studied in different trials in patients with cervical intraepithelial neoplasia II/III (CIN II/III) (NCT02139267, NCT02596243), and its efficacy in a cohort of 64 CIN III patients has been reported recently.\(^4\) In another interventional study, the efficiency of GX-188E in combination with GX-I7, interleukin-7 (IL-7) or imiquimod is being tested in CINIII patients (NCT03206138). VGX-3100 (Inovio Pharmaceuticals) is another DNA vaccine consisting of plasmids encoding modified E6 and E7 genes of HPV16/HPV18. The efficiency and safety of VGX-3100 combined with INO-9012 (a plasmid encoding IL-12), labelled INO-3112, was tested in a phase I/IIa trial in patients with recurrent or persistent cervical cancer (NCT02172911). Another phase III trial is active on patients with CIN II or CIN III associated with HPV16/HPV18 (NCT03185013). VB10.1 (Vaccibody AS6) is another DNA vaccine encoding a chimeric protein composed of an HPV16 E6/E7 fusion, a dimerization domain and an MIP-1α sequence that binds to antigen-presenting cells. VB10.1 was tested recently in woman with HPV16 (+) CIN II/III in a phase I/IIa (NCT02529930) and reported to be safe and induce E6/E7-specific CD8+ T cell responses.\(^4\) PNGVL4a-CRT/E7 (detox) is another promising DNA vaccine that induced robust immune response in HPV16 CIN II/III patients (NCT00988559).\(^4\) This vaccine encodes calreticulin, which is linked to a detoxified form of HPV16 E7 and has been also evaluated for treating head and neck cancer patients in a phase I clinical study (NCT01493154).

Genome editing tools

It has been shown recently that genome editing tools such as clustered regularly interspaced short palindromic repeats/Cas9 protein (CRISPR/Cas9), zinc finger nucleases (ZFNs) and transcription activator-like effector nuclease (TALENs) can decrease tumorigenicity in HPV16/18 in vitro and in vivo models.\(^4\) ZFN-603 and ZFN-758 can cleave the HPV16/18 E7 oncogene and reduce the expression of E7 leading to apoptosis of tumour cells. They are being evaluated in a phase I clinical study for the treatment of HPV16- or HPV18-positive CIN (NCT02800369). TALEN and CRISPR/Cas9 targeting HPV16 and HPV18 E6/E7 are also being evaluated in a phase I study for the treatment of HPV (+) CIN patients (NCT03057912).

CELL-BASED THERAPIES

In cell-based therapy, DCs, B cells or T cells are isolated from the patient, transduced ex vivo to express or target a specific antigen and infused back to the same patient. Ongoing clinical trials testing adoptive cell therapies for the treatment of cervical cancer are summarized in Table 4.

---

**Table 3. (Continued)**

| Agent Type | Clinical phase | Start Date | Completion Date | Reference |
|------------|----------------|------------|-----------------|-----------|
| ZFN-603/ZFN-758 Zinc finger nuclease | HPV16/18 | Dec. 2016 | July. 2017\(^a\) | NCT02800369 |
| TALEN/CRISPR/Cas9 Genome editing tools | E7 | Jan. 2018 | Jan. 2019 | NCT03057912 |

\(^a\)Active, not recruiting

---

© 2020 The Authors. Immunology published by John Wiley & Sons Ltd, Immunology, 163, 33–45
Clinical studies using adoptive T cell therapy (ATC) strategies for the treatment of metastatic or recurrent cervical cancer have shown encouraging results. The first study that explored ATC in cervical cancer was performed by Stevanović et al. on nine patients with HPV18- or HPV16-associated metastatic cervical cancer, who were treated with tumour-infiltrating lymphocytes (TILs) expanded ex vivo. Ramos et al. showed that HPV-specific T cells (called HPVST) derived from patients with HPV(+) cancers could be useful for immunotherapy of HPV-associated cancers. HPVST have been engineered to be resistant to TGF-β. In an ongoing phase I clinical trial (NCT02379520), the safety dose and durability of HPVST is being studied in patients with recurrent HPV-associated cancers in combination with nivolumab. It has been also shown that HPV-TILs can cause tumour regression in HPV-associated cancers (NCT01585428). Nevertheless, the process of isolating and expanding tumour-specific T cells is very labour and cost-intensive and not all patients have HPV-reactive peripheral or infiltrating T cells. Therefore, an ‘off-the-shelf’ approach with genetically engineered T cells would be desirable.

Chimeric antigen receptor (CAR) T cell

CAR T cells are engineered T cells expressing a single-chain fragment variable (scfv), which can recognize a tumour-associated antigen (TAA). They also utilize CD3-related components and costimulatory domains as intracellular signalling machinery. CAR T cells are MHC-independent and can activate the T cells upon binding the antigens expressed on the surface of the tumour cells. A phase I/II study (NCT03356795) evaluates the safety and efficacy of CAR T cells in cervical cancer patients whose tumour cells express TAAs such as GD2, PSMA, Mucl, mesothelin or other markers positive for cervical cancer. In this study, T cells are isolated from peripheral blood mononuclear cells (PBMCs) obtained through apheresis from cervical cancer patients positive for the respective TAAs. Then, the T cells are genetically modified to become TAA-specific CAR T cells and administered to the patient by intravenous infusion. The study also assessed the persistence, proliferation and activation of CAR T cells in the peripheral blood of patients.

Engineered TCR T cell therapy

The most relevant oncoproteins of HR-HPVs are nuclear and do not show on the surface of the tumour cells. A phase I/II study (NCT03356795) evaluates the safety and efficacy of CAR T cells in cervical cancer patients whose tumour cells express TAAs such as GD2, PSMA, Mucl or mesothelin. In this study, T cells are isolated from peripheral blood mononuclear cells (PBMCs) obtained through apheresis from cervical cancer patients positive for the respective TAAs. Then, the T cells are genetically modified to become TAA-specific CAR T cells and administered to the patient by intravenous infusion. The study also assessed the persistence, proliferation and activation of CAR T cells in the peripheral blood of patients.

| Agent | Type | Clinical phase | Start date | Completion date | Reference number |
|-------|------|----------------|------------|----------------|-----------------|
| BVAC-C | Cell-based therapy (B cell/monocyte) | I/II | Oct. 2016 | Aug. 2020 | NCT02866006 |
| HPVST /Cytoxan/fludarabine /nivolumab | HPV-specific T cells /chemotherapy /anti-PD-1 | I | Sept. 2015 | Oct. 2033 | NCT02379520 |
| Tumour-infiltrating lymphocytes / fludarabine /cyclophosphamide /aldesleukin | Adoptive cell transfer /chemotherapy /IL-2 | II | Apr. 2012 | Aug. 2016 | NCT01585428 |
| CAR T cell | Anti-GD2, PSMA, Mucl, mesothelin or other markers positive for cervical cancer | I/II | Nov. 2015 | Dec. 2020 | NCT03356795 |
| Engineered TCR T cell /fludarabine/ cyclophosphamide /aldesleukin | E6 (29-38)-reactive TCR /chemotherapy/IL-2 | I/II | Oct. 2014 | June 2016 | NCT02280811 |
| Engineered TCR T cell /aldesleukin | E6 (29-38)-reactive TCR /IL-2 | I | Jan. 2018 | May 2019 | NCT03197025 |
| Engineered TCR T cell /anti-PD-L1 | E6 (29-38)-reactive TCR | I | Sept. 2018 | Aug. 2021 | NCT03578406 |
| Engineered TCR T cell /fludarabine/ cyclophosphamide /aldesleukin | E7 (11-19)-reactive TCR /chemotherapy/IL-2 | I/II | Jan. 2017 | Jan. 2026 | NCT02858310 |
| Engineered TCR T cell | E7-reactive TCR | II | Oct. 2019 | June 2020 | NCT03937791 |
| KITE-439 /cyclophosphamide /fludarabine | HPV16 E7 T-cell receptor engineered T cells /chemotherapy | I | June 2019 | Feb. 2037 | NCT03912831 |
Several approaches have been described to identify tumour-specific T cells: (i) isolation of HPV-reactive T lymphocytes from patients experiencing tumour regression; (ii) immunization with human oncogenic proteins of transgenic murine models expressing human HLA; and (iii) generation of CTLs by in vitro stimulation of T cells extracted from patients or healthy donors. After having isolated a population of T cells reactive to the target pMHC, their TCRs are identified by single-cell transcriptional analysis.

Figure 2. Workflow for the identification of tumour-specific TCR sequences and for construction of engineered TCR T cells. (A) Reactive CTLs to a specific epitope can be obtained through different strategies: (i) extraction from patients suffering from the tumour under study; (ii) immunization of transgenic mice expressing human HLA (humanized antigen presentation) with a tumour-specific or tumour-associated antigen; and (iii) in vitro generation of reactive CTLs by stimulation of PBMCs from healthy donors or patients. (B) The complete sequences of TCRs of reactive CTLs are identified based on entire transcriptome or single-cell platforms. (C) The candidate TCR genes are engineered to include in tandem: TCR-β variable (βV)–murine constant region of β chain (β-mC)–Furin-P2A–TCR-α variable (αV)–murine constant region of α chain (α-mC). Then, naïve T cells or a TCR-α/β T-cell line is transduced with a lentiviral vector expressing the fusion gene to generate engineered TCR T cells that are expanded for further studies. (D) The engineered TCR T cells are then characterized for antigen affinity and avidity and for functionality by in vitro and in vivo assays.

© 2020 The Authors. Immunology published by John Wiley & Sons Ltd, Immunology, 163, 33–45
sequencing. Several methods, based on cDNA library preparation, provide entire transcripts of the TCR chains: multiplex PCR, target enrichment and 5' RACE. Furthermore, single-cell sequencing technologies, such as single-cell RT-PCR and paired seq, can identify the TCR repertoire at single-cell level. The ICELL8 single-cell system of Takara Bio USA, Inc. and 10XGenomics, Inc. also offers platforms for V(D)J analysis at single-cell level58 (Figure 2B). Once HPV-specific TCRs have been identified and cloned, their TCR-α and TCR-β genes are delivered to a TCR-deficient human T cell line, such as JurkatΔ76, for further characterization. Gene delivery can be achieved by RNA or plasmid DNA transfections, or by using a viral vector.59–61 Due to its high efficiency and long-term expression, virus-mediated delivery is usually preferred, especially using adeno-associated viruses, gammaretrovirus and lentivirus62,63 (Figure 2C). Subsequently, the engineered T cells undergo in vitro and in vivo functionality and avidity tests (Figure 2D).

Design of lentiviral vectors expressing engineered TCRs

It has been shown that using the murine constant region of TCRs can increase cytokine secretion signals and reduce the chance of mispairing of transgenic and endogenous TCRs.64 Moreover, introducing an additional disulphide bond and mutations in the murine constant region to introduce hydrophobic amino acids can enhance structural avidity, that is the binding strength of their TCRs to pMHC.65,66 Sequences encoding the alpha and beta chains are placed sequentially on the same open reading frame and are expressed as a fusion protein. A Furin cleavage site and a self-cleaving 2A sequence are added between alpha and beta chains. Furin is a member of the proprotein convertase family, which cleaves proteins downstream of basic amino acids such as arginine and lysine.66 2A self-cleaving peptides (2A peptides) are derived from viruses, and the most prevalent are as follows: P2A, E2A, F2A and T2A. Based on recent studies, P2A, derived from porcine teschovirus 1, is more efficient than others.67 For a more effective function, it is recommended that a glycine-serine spacer, such as GSG or SGSG, is included between the Furin cleavage site and the 2A peptides.68 A schematic representation of an engineered TCR gene is depicted in Figure 2C.

Structural avidity characterization of engineered TCR T cells

After having evidence showing that the engineered TCR T cells are able to recognize their target epitope on MHC class I, their structural avidity has to be measured. Nauert et al69 described a method by which the dynamic dissociation (Koff rate) can be quantitatively measured. This assay is based on reversible Streptamer including an engineered streptavidin, called as Strep-Tactin®, and small peptides with high affinity to Strep-Tactin (Strep-tags®), which are linked to fluorescently labelled monomers of the epitopes under study.

The binding of engineered TCR T cells to the target cells can be analysed also using the LigandTracer® instrument (Ridgeway Instruments AB). LigandTracer® detects the interaction of labelled molecules with cells in real time. The instrument has an inclined rotating platform on which the dish is placed. On one side of the Petri dish, the target cell is immobilized and pulsed with the desired peptides. The dish is placed on the rotating support, and the background fluorescence is measured. Then, the engineered TCR T cells, labelled with carboxyfluorescein succinimidyl ester, are added to the other side of the Petri dish. The rotation starts, and binding of the T cells to the target cells is measured by subtraction of the fluorescent signal on the side of the target cells from that of the side of the plate without target cells.70

Surface plasmon resonance (SPR) is another approach that has been used extensively to analyse TCR-pMHC interaction.71 In this technique, biotinylated pMHC is fixed covalently to a streptavidin-coupled sensor chip. Biotinylated pMHC loaded with an irrelevant epitope is used as a control. Then, the engineered TCR T cell suspension is injected and flows over the chip. Due to the binding of TCR to pMHC, the intensity of signal results increased.72 A more recent system, the Cell Avidity Analyzer z-Movi™ (Lumicks), uses target cells or ligands immobilized on the surface of a chip through which the T cells are circulated. Then, an acoustic force ramp is applied by which cells are progressively flushed out. Low avidity cells require less force to be separated from their targets. The interaction strength of effector to target cells is measured over time so that each effector cell population is characterized both absolute and relative to other populations by gradually increasing the force.

Assays for evaluating the function of engineered TCR T cells

The production of cytokines (IFN-γ, IL-2 and TNF-α) upon binding to target cells can be measured as an indication of functional engineered TCR T cells. In these assays, T2 or 293-A2 cells are pulsed with E7-derived peptides and co-cultured with E7-specific engineered TCR T cells. Detection of these cytokines above background levels (i.e. those obtained with irrelevant peptide) indicates specific activation.73,74

The cytolytic activity of T cells has been classically assessed by the chromium (51Cr) release assay. However, bioluminescence imaging and real-time cell assays are non-invasive and there is no need for prior labelling of the cells. The xCELLigence system is one such assay in
which electrical impedance is measured to determine cell viability. The read-out of such experiments is shown as cell index over time by which the lower the cell index, the higher the lysis rate of target cells.74

Measuring transcription factor activity upon TCR-pMHC engagement can also reveal the activation of T cells. Nuclear factor ‘kappa-light-chain-enhancer’ of activated B cells (NF-κB), nuclear factor of activated T cells (NFAT) and activator protein 1 (AP-1) are transcription factors playing important roles in T cell differentiation, proliferation and activation. A triple-parameter reporter has been derived from Jurkat J76 cells, in which responsive elements for the transcription factors induce the expression of fluorescent proteins.75 There are also commercially available T cell activation bioassays for measuring NFAT and the secretion of IL-2, an indirect sign of NFAT activation, and the read-out is based on luminescence. Importantly, the engineered TCR T cells should be tested in vivo to confirm their antitumour activity (Figure 2D). Engineered T cells that meet the functional and structural avidity criteria and show efficient tumour eradication in vivo can be then considered as good candidates for clinical trials.

Clinical trials using engineered TCR T cells targeting HPV+cancers

In an exploratory in vitro study with TILs isolated from tumour fragments of a patient with metastatic HPV16 (+) anal cancer, Draper et al. used the TCR engineering approach to retarget T cells against the E6 protein of HPV16.73 Using the sequence of the dominant E6-reactive TCR clonotype, which recognized HLA-A*02:01/E629-38 tetramers, genetically engineered T cells were generated from PBMCs of HPV16 (+) cancer patients. Based on this, a phase I/II trial (NCT02280811) was conducted with 12 HPV (+) cancer patients. Two partial responses lasting up to 6 months were reported.

TCRcure Biopharma Ltd introduced another E6-specific engineered TCR T cell, which is being evaluated in a phase I study with patients with HPV16 (+) cancers (NCT03578406). Recently, Jin et al.74 isolated and sequenced T cell clone from cervix-infiltrating lymphocytes, which showed high HLA-A*02:01/E711-19 tetramer binding and sequenced its TCR. After introducing slight modifications (reversing alpha and beta chain order, adding an extra disulphide bond and several hydrophobic substitutions and cloning into the MSGV1 retrovirus vector), they generated engineered TCR T cells and tested their avidity and efficacy in vitro and in a mouse model. Later on, a phase I/II clinical trial (NCT02858310) was started to determine the safety and efficacy of E7 TCR-engineered T cells in HPV16-associated cancers, which is still ongoing. They also evaluate the effect of this E7 TCR T cells for vulvar HSIL in a phase II clinical study (NCT03937791).

Furthermore, a recent study has revealed information about the TCR repertoire of cervical cancer patients experiencing tumour remission or failed to clear tumour.76 This kind of data can provide a platform for further investigation to find other possible TCR sequences to target HPV-positive cancers.

CONCLUSION AND FUTURE PERSPECTIVE

Antibodies against immune checkpoint inhibitors, such as pembrolizumab, have shown antitumour activity in patients with HPV16 (+) PD-L1-expressing tumours. However, these inhibitors have to be used in combination with radiotherapy, chemotherapy or therapeutic vaccines. Among therapeutic vaccines targeting HPV16, VGX-3100 and ADXS11-001 are in phase III trials, and they could get clinical approval soon. However, most therapeutic vaccines are still in early trial phases. Approaches to combat the immune-evasive capacity of the tumour microenvironment and improving the trafficking of genetically engineered T cells into tumour tissues are important determinants for successful cell-based immunotherapies. Due to the complex nature of HPV-positive carcinoma, combination of different immunotherapeutic approaches will be necessary.

ACKNOWLEDGEMENT

Elham Fakhr acknowledges the support from the German Academic Exchange Service (DAAD) for PhD fellowship. Živa Modic is supported by Ad futura Scholarship, granted by Public Scholarship, Development, Disability and Maintenance Fund of the Republic of Slovenia. Open access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interests.

DATA AVAILABILITY STATEMENT

Not applicable.

REFERENCES

1 de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324: 17–27.
2 Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27.
3 Elgren K, Kalantari M, Moerberger B, Hagnar D, Dillner J. A population-based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol. 2000;183:561–2.
4 Wintzenen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res. 2004;64:3878–84.
50 Ramos CA, Narala N, Vyas GM, Lem AM, Gerdermann U, Strugis EM, et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother. 2013;36:66–76.

51 Stevanovic S, Helman SR, Wunderlich JR, Langham MM, Doran SL, Kwong MLM, et al. A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clin Cancer Res. 2019;25:1486–93.

52 Baruch EN, Berg AL, Beser MJ, Schachter J, Markel G. Adoptive T cell therapy: an overview of obstacles and opportunities. Cancer 2017;123(51):2154–62.

53 Posebrabhim M, Sadeghi S, Fakhr E, Abaraz MF, Poortahmahsebi V, Kheirrohali A, et al. Production of CAR T cells by GMP-grade lentiviral vectors: latest advances and future prospects. Curr Rev Clin Lab Sci. 2019;56:393–419.

54 Ping Y, Liu C, Zhang Y. T cell receptor-engineered T cells for cancer treatment: current status and future directions. Protein Cell. 2018;9:254–66.

55 de Witte MA, Coccoris M, Walkers MC, van den Boom MD, Mesman EM, Song JY, et al. Targeting self-antigens through allogeneic TCR gene transfer. Blood 2006;108:870–7.

56 Hoffmann TK, Arsov C, Schirau K, Bas M, Friebe-Hoffmann U, Klussmann JP, et al. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer. 2006;118:1984–91.

57 Sharpe M, Mount N. Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech. 2015;8:337–50.

58 Rosati E, Dowds CM, Liakou I, Henriksen EKK, Karlsen TH, Franke A. Overview of methodologies for T cell receptor repertoire analysis. BMC Biotechnol. 2017;17:61.

59 Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC, Restifo NP, et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther. 2006;13:151–9.

60 Williams JA. Vector design for improved DNA vaccine efficacy, safety and production. Vaccines. 2013;1:225–49.

61 Gaspar V, de Melo-Diogo D, Costa E, Moreira A, Queiroz J, Pichon C, et al. Minicircle DNA vectors for gene therapy: advances and applications. Expert Opin Biol Ther. 2015;15:353–79.

62 Vargas JE, Chicyaham L, Stein JT, Tanuri A, Delgado-Canedo A, Bonamino MH. Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives. J Transl Med. 2016;14:288.

63 Milone MC, O’Doherty U. Clinical use of lentiviral vectors. Leukemia 2018;32:1529–41.

64 Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 2006;66:8878–86.

65 Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T cell receptors with a second disulfide bond. Cancer Res. 2007;67:5898–903.

66 Haga-Friedman A, Hoovitz-Fried M, Cohen CJ. Incorporation of transmembrane hydrophilic mutations in the TCR enhances its surface expression and T cell functional avidity. J Immunol. 2012;188:5538–46.

67 Liu Z, Chen O, Wall JB, Zheng M, Zhou Y, Wang L, et al. Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector. Sci Rep. 2017;7:11933.

68 Yang S, Cohen CJ, Peng FD, Zhao Y, Cassaud L, Yu Z, et al. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther. 2008;15:1411–23.

69 Nauert H, Steenberger C, Mohr F, Weissbrich B, Schimmann M, Germeroth L, et al. Flow cytometry-based TCR-ligand Koff-rate assay for fast avidity screening of even very small antigen-specific T cell populations ex vivo. Cytometry A. 2016;89:816–25.

70 Hillerdal V, Bora R, Bjorkelund H, Andersson K, Essand M. Avidity characterization of genetically engineered T cells with novel and established approaches. BMC Immunol. 2015;16:27.

71 Pienpenrnik KH, Gloos BE, Armstrong KM, Baker RM. Methods for quantifying T cell receptor binding affinities and thermodynamics. Methods Enzymol. 2009;466:359–81.

72 Garcia KC, Radu CG, Ho I, Ober RJ, Ward ES. Kinetics and thermodynamics of T cell receptor- autoantigen interactions in murine experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2001;98:6518–23.

73 Draper LM, Kwong ML, Gross A, Stevanovic S, Tran E, Kerkar S, et al. Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6. Clin Cancer Res. 2015;21:4431–9.

74 Jin BY, Campbell TM, Draper LM, Stevanovic S, Weissbrich B, Yu Z, et al. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight. 2018;3:e99488.

75 Zuti S, Leitner J, Schmetterer K, Doel-Perez J, Majdic O, Grabmeier-Piiferhammer K, et al. Assessment of costimulation and co-inhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-kappaB, NFAT and AP-1. J Immunol Methods. 2016;430:10–20.

76 Lang Kuh S, Lin SW, Hua X, Schliman M, Burk RD, Rodriguez AC, et al. T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study. PLoS One 2018;13:e0178167.